Drug Database
Back to search

Poland· PL-100314675

Lapixen

A lacidipine product containing lacidipinum, registered in Poland by Biofarm Sp. z o.o.. The same ATC class is registered in 7 of our 19 countries.

ATC C08CA09

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedLapixenATCC08CA09REGISTER NO.PL-100314675PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lacidipinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lacidipine is registered in 7 of 19 countries.

Countries holding a registration under ATC C08CA09 (lacidipine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 4 of them publish a price we can compare per daily dose
Search lacidipine products by name

Lacidipine · ATC C08CA09

7 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Italyprice
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lacidipine costs, country by country.

Normalised to the WHO defined daily dose (4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Lacidipine · price per daily dose (4 mg)

USD · FX 28 Sept 2026

  • IT Italy$0.37
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Lacidipinum
Manufacturer
Biofarm Sp. z o.o.
Country
Poland (PL)
ATC code
C08CA09
ATC class
Lacidipine
Defined daily dose
4 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

2 priced
  • gtin
    05909991134884
  • gtin
    05909991134891
  • gtin
    05909991134907
    28 szt.
    PLN 8.32
  • gtin
    05907695215205
    56 szt.
    PLN 15.82

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for lacidipine.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lacidipine against other medicinesHow interaction checks work

Lacidipine · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Lacidipine in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lacidipine products

Authorised across Europe · EMA

The same active substance is authorised in 17 EEA countries. Names it is sold under:

  • Bulgaria · Ласипил
  • Czechia · Lacipil
  • Denmark · Lacidipin Teva
  • Estonia · Lacipil, Prelum
  • Spain · Lacidipino Teva, Lacimen
  • United Kingdom (Northern Ireland) · Lacidipine Dr. Reddy's Laboratories (Uk), Lacidipine Generics [uk] Ltd
  • Greece · Lacipil
  • Croatia · Lacidipin Belupo, Lacipil
  • Hungary · Lacipil
  • Italy · Aponil, Lacidipina Doc Generici
  • Lithuania · Lacipil, Prelum
  • Latvia · Lacipil, Prelum
  • Malta · Lacidipine Doc Generici
  • Netherlands · Lacidipine Double-E Pharma, Lacidipine Teva
  • Portugal · Lacipil
  • Slovenia · Lacidipin Teva, Lacipil
  • Slovakia · Lacipil

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f615ca04-3899-4175-a38d-df46a5177751
GET /v1/drugs/f615ca04-3899-4175-a38d-df46a5177751?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "2 mg",
  "packaging": "05909991134884 ¦ Rp ¦ 90809\n7 tabl.\n05909991134891 ¦ Rp ¦ 90810\n14 tabl.\n05909991134907 ¦ Rp ¦ 90811\n28 tabl.\n05907695215205 ¦ Rp ¦ 109087\n56 tabl.",
  "substance": "Lacidipinum 2 mg",
  "common_name": "Lacidipinum",
  "pl_product_id": "100314675",
  "pozwolenie_nr": "21789",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about lacidipine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console